Marina Vivarelli1,2, Manuela Colucci3, Antonio Gargiulo1, Chiara Bettini1, Anna Lo Russo4, Francesco Emma1,2. 1. Division of Nephrology, Department of Pediatric Subspecialties, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 2. Renal Diseases Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale S. Paolo 15, 00146, Rome, Italy. 3. Renal Diseases Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale S. Paolo 15, 00146, Rome, Italy. Manuela.colucci@opbg.net. 4. Core Facilities, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Abstract
BACKGROUND: Effectiveness of rituximab in pediatric idiopathic nephrotic syndrome suggests that B cells play a pathogenic role. We tested safety and efficacy of the B-cell-modulating agent belimumab in frequently relapsing nephrotic syndrome (FRNS). METHODS: An open-label, prospective, single-arm pilot study (EUDRACT 2017-003839-11) was designed to treat 10 children with FRNS with i.v. belimumab for 12 months. Prednisone was tapered/stopped. Safety, number of relapses, cumulative prednisone dose and B-cell subset "levels" are referred to both B cell subset and immunoglobulin. RESULTS: Five patients were enrolled, and four reached the primary 6-month endpoint. Of these, two completed the 12-month endpoint. Three patients experienced ≥2 relapses while on belimumab, requiring additional immunosuppression. Compared to the 6 months before belimumab treatment, the mean number of relapses (1.4 vs. 2, p=0.21) and the mean cumulative prednisone dose (1.86 vs. 2.62 g/m2, p=0.17) were not significantly reduced during the 6 months on belimumab. This study was terminated by the steering committee after the interim evaluation because belimumab failed to show clear benefits to counterbalance the inconvenience of monthly i.v. infusion. During follow-up, total and mature-naïve B cells decreased, while no change in memory B-cells was observed. Serum immunoglobulins remained stable. No infusion reaction was observed. CONCLUSIONS: Short-term treatment with belimumab in pediatric FRNS was well tolerated. The number of patients was too small to draw conclusions on efficacy. Nonetheless, we did not observe clear improvements. The burden of monthly in-hospital i.v. infusions outweighed potential benefits. Persistence of circulating memory B cells supports their pathogenic role in the disease. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Effectiveness of rituximab in pediatric idiopathic nephrotic syndrome suggests that B cells play a pathogenic role. We tested safety and efficacy of the B-cell-modulating agent belimumab in frequently relapsing nephrotic syndrome (FRNS). METHODS: An open-label, prospective, single-arm pilot study (EUDRACT 2017-003839-11) was designed to treat 10 children with FRNS with i.v. belimumab for 12 months. Prednisone was tapered/stopped. Safety, number of relapses, cumulative prednisone dose and B-cell subset "levels" are referred to both B cell subset and immunoglobulin. RESULTS: Five patients were enrolled, and four reached the primary 6-month endpoint. Of these, two completed the 12-month endpoint. Three patients experienced ≥2 relapses while on belimumab, requiring additional immunosuppression. Compared to the 6 months before belimumab treatment, the mean number of relapses (1.4 vs. 2, p=0.21) and the mean cumulative prednisone dose (1.86 vs. 2.62 g/m2, p=0.17) were not significantly reduced during the 6 months on belimumab. This study was terminated by the steering committee after the interim evaluation because belimumab failed to show clear benefits to counterbalance the inconvenience of monthly i.v. infusion. During follow-up, total and mature-naïve B cells decreased, while no change in memory B-cells was observed. Serum immunoglobulins remained stable. No infusion reaction was observed. CONCLUSIONS: Short-term treatment with belimumab in pediatric FRNS was well tolerated. The number of patients was too small to draw conclusions on efficacy. Nonetheless, we did not observe clear improvements. The burden of monthly in-hospital i.v. infusions outweighed potential benefits. Persistence of circulating memory B cells supports their pathogenic role in the disease. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: W Winn Chatham; Daniel J Wallace; William Stohl; Kevin M Latinis; Susan Manzi; W Joseph McCune; Dana Tegzová; James D McKay; Hilario E Avila-Armengol; Tammy O Utset; Z John Zhong; Douglas R Hough; William W Freimuth; Thi-Sau Migone Journal: J Rheumatol Date: 2012-06-15 Impact factor: 4.666
Authors: Gemma D Banham; Shaun M Flint; Nicholas Torpey; Paul A Lyons; Don N Shanahan; Adele Gibson; Christopher J E Watson; Ann-Marie O'Sullivan; Joseph A Chadwick; Katie E Foster; Rachel B Jones; Luke R Devey; Anna Richards; Lars-Peter Erwig; Caroline O Savage; Kenneth G C Smith; Robert B Henderson; Menna R Clatworthy Journal: Lancet Date: 2018-06-14 Impact factor: 79.321
Authors: Ellen M Ginzler; Daniel J Wallace; Joan T Merrill; Richard A Furie; William Stohl; W Winn Chatham; Arthur Weinstein; James D McKay; W Joseph McCune; Z John Zhong; William W Freimuth; Michelle A Petri Journal: J Rheumatol Date: 2013-11-01 Impact factor: 4.666
Authors: Pietro Ravani; Alice Bonanni; Roberta Rossi; Gianluca Caridi; Gian Marco Ghiggeri Journal: Clin J Am Soc Nephrol Date: 2015-11-19 Impact factor: 8.237
Authors: Christine Barrett; Lisa C Willcocks; Rachel B Jones; Ruth M Tarzi; Robert B Henderson; Gengqian Cai; Sophie I Gisbert; Alexandra S Belson; Caroline O Savage Journal: Nephrol Dial Transplant Date: 2020-04-01 Impact factor: 5.992
Authors: Manuela Colucci; Rita Carsetti; Jessica Serafinelli; Salvatore Rocca; Laura Massella; Antonio Gargiulo; Anna Lo Russo; Claudia Capponi; Nicola Cotugno; Ottavia Porzio; Andrea Onetti Muda; Paolo Palma; Francesco Emma; Marina Vivarelli Journal: Front Immunol Date: 2019-07-16 Impact factor: 7.561